1. Division of Pathology, The Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway.
2. Department of Gynaecology, Ziekenhuizen Oost Limburg, Genk, Belgium
3. Faculty Division The Norwegian Radium Hospital, Medical Faculty, University of Oslo, Norway.
4. Division of Obstetrics and Gynaecology, The Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway.
5. Institute of Medical Informatics, The Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway.
By using immunohistochemistry we investigated the expression of EphA2 and EphrinA-1 in 217 early squamous cell cervical carcinomas and examine their prognostic relevance. For EphA2 expression, 21 tumors (10%) showed negative, 108 (50%) weak positive, 69 (32%) moderate positive and 19 (9%) strong positive, whereas for EphrinA-1 expression, 33 tumors (15%) showed negative, 91 (42%) weak positive, 67 (31%) moderate positive and 26 (12%) strong positive. In univariate analysis high expression (strong staining) of EphrinA-1 was associated with poor disease-free (P = 0.033) and disease-specific (P = 0.039) survival. However, in the multivariate analyses neither EphrinA-1 nor EphA2 was significantly associated to survival. The increased levels of EphA2 and EphrinA-1 in a relative high number of early stage squamous cell carcinomas suggested that these two proteins may play an important role in the development of a subset of early cervical cancers. However, EphA2 and EphrinA-1 were not independently associated with clinical outcome.
Keywords: Immunohistochemistry, early cervical cancer, EphA2 and EphrinA-1